Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.AstraZeneca has signed an agreement with Europe’s Inclusive Vaccines Alliance (IVA) to supply up to 400 million doses of the Covid-19 vaccine, developed by the University of Oxford, by the end of this year.
IVA, led by Germany, France, Italy and the Netherlands, expects the deal to boost the vaccine’s supply, making it available to other participating European countries.
The Covid-19 vaccine, AZD1222, is currently in Phase II / III clinical trial in the UK, with other late-stage trials to be conducted in multiple countries.